Device Firms Will Collaborate With Pharma Rather Than Merge, Medtronic Exec Says
This article was originally published in The Pink Sheet Daily
Medical device makers will continue to build their in-house expertise in pharmaceuticals and biologics, but will leave the drug and biologic discovery process to outside partners, Medtronic’s chief operating officer predicts.
You may also be interested in...
The yet-to-be-named medtech company will focus on orthopedic implants and bracing and recovery devices.
Device Week, 5 March 2021 – Remote Monitoring Reimbursement, T-cell Diagnostics, And A Digital Health Feature
In this week's podcast, managing editor Marion Webb discusses a new monthly digital health roundup which will soon feature on Medtech Insight. Managing editor Reed Miller discusses reimbursement difficulties as it applies to remote cardiac monitoring. UK-based reporter Barnaby Pickering gives an overview of an interview with the chief medical officer of Adaptive Biotechnologies about its new T-Detect platform.
Hillrom is reconsidering its planned $375m acquisition of Bardy Diagnostics because of Novitas' plan to cut Medicare reimbursement for extended cardiac monitoring. Bardy is suing to complete the deal.